Israeli organic goods chemist Raphael Mechoulam has by no means smoked a joint, but he has spent decades studying the chemistry and pharmacology of cannabinoids and was the initially to isolate delta-9 tetrahydrocannabinol (THC) in its pure type in the 1960s.
Subsequent month, Mechoulam will be the recipient of an award in recognition of his revolutionary analysis and contributions to the understanding of the cannabis plant.
The Oakland-primarily based Arcview Group announced on Friday that they will be honoring Mechoulam with a lifetime achievement award and a $10,000 analysis grant at the Arcview Investor Forum: The Evolution of Cannabis: 2020 at 7:00 p.m. on Thursday, October three in New York.
“Cannabis analysis has by no means been far more essential to the future of our business, specially as the federal government starts processing dozens of pending applications for the methods important to enhance access to marijuana analysis,” stated Arcview Group co-founder and CEO Troy Dayton. “As the initially particular person to synthesize THC, recognize the endocannabinoid technique and illustrate the medicinal properties of cannabis, no one particular is far more deserving than Raphael of our Lifetime Achievement Award. We can not wait to see what he uncovers subsequent.”
The award will be dubbed the Arcview Raphael Mechoulam Lifetime Achievement Award for future recipients to preserve and continue to honor Mechoulam’s function.
In addition to recognizing Mechoulam for his contributions to cannabinoid analysis, the Arcview Investor Forum will bring with each other fund managers, CEOs, and crucial investors from some of the largest cannabis businesses in the business.
Seven cannabis businesses have been chosen by Arcview Investor Network members to present to investors in a Shark Tank-style format through the forum.
Network members who are interested in attending the Investor Forum may well register at the Arcview web-site.